Literature DB >> 26155514

Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.

Piyush Ranjan1, Avinash Chakrawarty2, Archana Kumari3, Jitendra Kumar4.   

Abstract

Patients with rheumatic diseases are susceptible to various infections throughout the course of the disease. The increased risk of infections can be attributed partly to the aberrant immune system and partly to the effect of immunosuppressive drugs used in the treatment of the disease. Immunization appears to be an excellent strategy to prevent infections in such patients. However, the effect of vaccines in these patients is modified due to disease per se and/or immunosuppressive drugs. Biological agents, that frequently increase the susceptibility to infections, are now being initiated earlier in the course of the disease and also for new indications. Thus, concerns regarding safety, efficacy and potential adverse effects of vaccines in these patients are more complex than in any other immunosuppressive conditions. Different patients show different amount of immunosuppression in response to disease modifying drugs. Besides, there is lack of adequately powered randomised controlled trials investigating the efficacy of a vaccine in terms of actual prevention of the disease. Pneumococcal and influenza vaccines are the most studied vaccines and they are strongly recommended in rheumatic patients. In general, live vaccines should be avoided among patients receiving high doses of immunosuppressive drugs. However, they may be given to patients receiving low dose steroids and methotrexate. Non-live vaccines may be administered as per the recommendations of national guidelines. There is necessity to increase awareness among patients and doctors towards promoting the appropriate and judicious use of vaccines in the patients with rheumatic diseases.

Entities:  

Keywords:  Immunosuppressive drugs; Live vaccines; steroids

Year:  2015        PMID: 26155514      PMCID: PMC4484106          DOI: 10.7860/JCDR/2015/14147.5972

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  31 in total

1.  Involvement of BCG scar in Kawasaki disease.

Authors:  Deyis Antony; P L Jessy
Journal:  Indian Pediatr       Date:  2005-01       Impact factor: 1.411

2.  A case-control study of serious autoimmune adverse events following hepatitis B immunization.

Authors:  David A Geier; Mark R Geier
Journal:  Autoimmunity       Date:  2005-06       Impact factor: 2.815

3.  Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  Ori Elkayam; Daphna Paran; Dan Caspi; Irena Litinsky; Michael Yaron; Darlene Charboneau; Jeffrey B Rubins
Journal:  Clin Infect Dis       Date:  2001-12-04       Impact factor: 9.079

Review 4.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

Review 5.  A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review.

Authors:  M R Geier; D A Geier
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

6.  Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study.

Authors:  Per Ljungman; Hareth Nahi; Annika Linde
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

7.  National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study.

Authors:  Elaine Thomas; Deborah P M Symmons; David H Brewster; Roger J Black; Gary J Macfarlane
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

8.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

9.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study.

Authors:  Lai-Shan Tam; Paul K S Chan; Suzanne C Ho; May M Y Yu; So-Fan Yim; Tak-Hong Cheung; Martin C S Wong; Edmund K Li
Journal:  J Rheumatol       Date:  2009-12-23       Impact factor: 4.666

View more
  2 in total

Review 1.  Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19.

Authors:  Michael R Yeaman
Journal:  Glomerular Dis       Date:  2021-08-25

2.  Live-attenuated vaccines in a cryopyrin-associated periodic syndrome patient receiving canakinumab treatment during infancy.

Authors:  Misa Watanabe; Ryuta Nishikomori; Yuki Fujimaki; Toshio Heike; Akira Ohara; Tsutomu Saji
Journal:  Clin Case Rep       Date:  2017-09-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.